Insurer’s Actos Lawsuit Claims Drug Companies Failed to Warn of Bladder Cancer Risk, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating Actos lawsuits on behalf of long-term users of the Type 2 diabetes medication who allegedly developed bladder cancer due to Actos.

Free Case Review
This is just the latest of thousand of lawsuits accusing these defendants of concealing information about the association between Actos and bladder cancer.

An insurance company has filed an Actos lawsuit ( in the U.S. District Court, Western District of Louisiana, alleging that the manufacturers of the Type 2 diabetes medication failed to warn that long-term use of the drug could increase a patient’s risk of developing bladder cancer. The complaint, which was filed on June 11, 2014, seeks to recoup the cost of medical bills incurred by Blue Cross and Blue Shield of Massachusetts Inc. for hundreds of alleged victims of Actos bladder cancer. Among other things, the Actos lawsuit claims that Takeda Pharmaceuticals, Co., Ltd. And Eli Lily & Co. were aware of the dangers associated with Actos, but refused to warn patients, physicians, and the medical community about its link to bladder cancer. (Case No. 6:14-cv-01159).

“This is just the latest of thousand of lawsuits accusing these defendants of concealing information about the association between Actos and bladder cancer. Our Firm also continues to receive Actos lawsuit inquiries from individuals who were allegedly harmed by the medication,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.

Actos Bladder Cancer Allegations
Court records show that the Actos bladder cancer litigation has been mounting since June 2011, when new information was added to the Actos label regarding its potential to cause bladder cancer. The U.S. Food & Drug Administration mandated the label change after interim results from a 10 year study suggested that taking Actos for more than 1 year was associated with a doubling of the risk of bladder cancer.

Since then, more than 3,000 product liability claims have been filed in the Western District of Louisiana on behalf of alleged Actos bladder cancer victims. (In re: Actos Product Liability Litigation, MDL No. 2299) Court filings indicate that the federal litigation completed its first trial of an Actos lawsuit in April. The case ended with a jury awarding the plaintiff $1.475 million in compensatory damages, along with $9 billion in punitive damages. (Case No. 12-cv-00064).

Individuals who allegedly developed bladder cancer due to their long-term use of Actos may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury-related damages. To find out more about Actos lawsuits, please visit Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website